EMMPRIN reduction via scFv-M6-1B9 intrabody affects α3β1- integrin and MCT1 functions and results in suppression of progressive phenotype in the colorectal cancer cell line Caco-2

Cancer Gene Therapy

Volumn 21, Issue 6, 2014, Pages 246-255

  Sangboonruang, S ^a   Thammasit, P ^a   Intasai, N ^a   Kasinrerk, W ^a   Tayapiwatana, C ^a   Tragoolpua, K ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CD147 ANTIGEN; CELL SURFACE PROTEIN; GELATINASE A; GELATINASE B; LACTIC ACID; MONOCARBOXYLATE TRANSPORTER 1; SCFV M6 1B9 INTRABODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 3; BSG PROTEIN, HUMAN; COTRANSPORTER; MONOCARBOXYLATE TRANSPORT PROTEIN 1; MONOCARBOXYLATE TRANSPORTER;

ARTICLE; CACO 2 CELL LINE; CANCER GENE THERAPY; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER CELL LINE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; ANTIBODY SPECIFICITY; CELL MOTION; COLORECTAL TUMOR; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANTIBODY SPECIFICITY; ANTIGENS, CD147; CACO-2 CELLS; CELL MOVEMENT; COLORECTAL NEOPLASMS; HUMANS; INTEGRIN ALPHA3BETA1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MONOCARBOXYLIC ACID TRANSPORTERS; SINGLE-CHAIN ANTIBODIES; SYMPORTERS;

EID: 84903593918     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2014.24     Document Type: Article

References (59)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Ang CS, Phung J, Nice EC. The discovery and validation of colorectal cancer biomarkers. Biomed Chromatogr 2011; 25: 82-99.
3. Huet E, Gabison EE, Mourah S, Menashi S. Role of emmprin/CD147 in tissue remodeling. Connect Tissue Res 2008; 49: 175-179.
4. Kanekura T, Chen X. CD147/basigin promotes progression of malignant melanoma and other cancers. J Dermatol Sci 2009; 57: 149-154.
5. Weidle UH, Scheuer W, Eggle D, Klostermann S, Stockinger H. Cancer-related issues of CD147. Cancer Genomics Proteomics 2010; 7: 157-169.
6. Tang J, Wu YM, Zhao P, Yang XM, Jiang JL, Chen ZN. Overexpression of HAb18G/CD147 promotes invasion and metastasis via alpha3beta1 integrin mediated FAK-paxillin and FAK-PI3K-Ca2+ pathways. Cell Mol Life Sci 2008; 65: 2933-2942.
7. Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 1999; 343(Pt 2): 281-299.
8. Baba M, Inoue M, Itoh K, Nishizawa Y. Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. Biochem Biophys Res Commun 2008; 374: 111-116.
9. Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 2005; 87: 361-368.
10. Aglund K, Rauvala M, Puistola U, Angstrom T, Turpeenniemi-Hujanen T, Zackrisson B et al. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol Oncol 2004; 94: 699-704.
11. Jouneau S, Khorasani N, DES P, Macedo P, Zhu J, Bhavsar PK et al. EMMPRIN (CD147) regulation of MMP-9 in bronchial epithelial cells in COPD. Respirology 2011; 16: 705-712.
12. Kontermann RE. Intrabodies as therapeutic agents. Methods 2004; 34: 163-170.
13. Williams BR, Zhu Z. Intrabody-based approaches to cancer therapy: status and prospects. Curr Med Chem 2006; 13: 1473-1480.
14. Uprichard SL. The therapeutic potential of RNA interference. FEBS Lett 2005; 579: 5996-6007.
15. Tragoolpua K, Intasai N, Kasinrerk W, Mai S, Yuan Y, Tayapiwatana C. Generation of functional scFv intrabody to abate the expression of CD147 surface molecule of 293A cells. BMC Biotechnol 2008; 8: 5.
16. Intasai N, Tragoolpua K, Pingmuang P, Khunkaewla P, Moonsom S, Kasinrerk W et al. Potent inhibition of OKT3-induced T cell proliferation and suppression of CD147 cell surface expression in HeLa cells by scFv-M6-1B9. Immunobiology 2009; 214: 410-421.
17. Meusser B, Hirsch C, Jarosch E, Sommer T. ERAD: the long road to destruction. Nat Cell Biol 2005; 7: 766-772.
18. Paganetti P, Calanca V, Galli C, Stefani M, Molinari M. beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide. J Cell Biol 2005; 168: 863-868.
19. Rein DT, Breidenbach M, Wu H, Han T, Haviv YS, Wang M et al. Gene transfer to cervical cancer with fiber-modified adenoviruses. Int J Cancer 2004; 111: 698-704.
20. Kanerva A, Hemminki A. Adenoviruses for treatment of cancer. Ann Med 2005; 37: 33-43.
21. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9: 1408-1412.
22. Nilsson M, Ljungberg J, Richter J, Kiefer T, Magnusson M, Lieber A et al. Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med 2004; 6: 631-641.
23. Carlson CA, Steinwaerder DS, Stecher H, Shayakhmetov DM, Lieber A. Rearrangements in adenoviral genomes mediated by inverted repeats. Methods Enzymol 2002; 346: 277-292.
24. Muramatsu T, Miyauchi T. Basigin (CD147): a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion. Histol Histopathol 2003; 18: 981-987.
25. Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/ extracellular matrix metalloproteinase inducer interactions. Cancer Res 2001; 61: 2276-2281.
26. Berditchevski F, Chang S, Bodorova J, Hemler ME. Generation of monoclonal antibodies to integrin-associated proteins. Evidence that alpha3beta1 complexes with EMMPRIN/basigin/OX47/M6. J Biol Chem 1997; 272: 29174-29180.
27. Wilson MC, Meredith D, Halestrap AP. Fluorescence resonance energy transfer studies on the interaction between the lactate transporter MCT1 and CD147 provide information on the topology and stoichiometry of the complex in situ. J Biol Chem 2002; 277: 3666-3672.
28. Chen X, Su J, Chang J, Kanekura T, Li J, Kuang YH et al. Inhibition of CD147 gene expression via RNA interference reduces tumor cell proliferation, activation, adhesion, and migration activity in the human Jurkat T-lymphoma cell line. Cancer Invest 2008; 26: 689-697.
29. Kuang YH, Chen X, Su J, Wu LS, Liao LQ, Li D et al. RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion. Cancer Lett 2009; 276: 189-195.
30. Su J, Chen X, Kanekura T. A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis. Cancer Lett 2009; 273: 140-147.
31. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J 2000; 19: 3896-3904.
32. Philp NJ, Ochrietor JD, Rudoy C, Muramatsu T, Linser PJ. Loss of MCT1, MCT3, and MCT4 expression in the retinal pigment epithelium and neural retina of the 5A11/ basigin-null mouse. Invest Ophthalmol Vis Sci 2003; 44: 1305-1311.
33. Li R, Pan Y, He B, Xu Y, Gao T, Song G et al. Downregulation of CD147 expression by RNA interference inhibits HT29 cell proliferation, invasion and tumorigenicity in vitro and in vivo. Int J Oncol 2013; 43: 1885-1894.
34. Chen L, Pan Y, Gu L, Nie Z, He B, Song G et al. ERK1/2 signalling pathway is involved in CD147-mediated gastric cancer cell line SGC7901 proliferation and invasion. Exp Biol Med (Maywood) 2013; 238: 903-912.
35. Mebratu Y, Tesfaigzi Y. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle 2009; 8: 1168-1175.
36. Lu Z, Xu S, ERK1/2 MAP. kinases in cell survival and apoptosis. IUBMB Life 2006; 58: 621-631.
37. Curtin KD, Meinertzhagen IA, Wyman RJ. Basigin (EMMPRIN/CD147) interacts with integrin to affect cellular architecture. J Cell Sci 2005; 118(Pt 12): 2649-2660.
38. Dai JY, Dou KF, Wang CH, Zhao P, Lau WB, Tao L et al. The interaction of HAb18G/ CD147 with integrin alpha6beta1 and its implications for the invasion potential of human hepatoma cells. BMC Cancer 2009; 9: 1-10.
39. Tang Y, Nakada MT, Rafferty P, Laraio J, McCabe FL, Millar H et al. Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Mol Cancer Res 2006; 4: 371-377.
40. Chetty C, Bhoopathi P, Joseph P, Chittivelu S, Rao JS, Lakka S. Adenovirusmediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther 2006; 5: 2289-2299.
41. Giannelli G, Bergamini C, Fransvea E, Marinosci F, Quaranta V, Antonaci S. Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. Lab Invest 2001; 81: 613-627.
42. Gorman JL, Ispanovic E, Haas TL. Regulation of matrix metalloproteinase expression. Drug Discov Today Dis Models 2011; 8: 5-11.
43. Bode W, Fernandez-Catalan C, Grams F, Gomis-Ruth FX, Nagase H, Tschesche H et al. Insights into MMP-TIMP interactions. Ann N Y Acad Sci 1999; 878: 73-91.
44. Gaide Chevronnay HP, Selvais C, Emonard H, Galant C, Marbaix E, Henriet P. Regulation of matrix metalloproteinases activity studied in human endometrium as a paradigm of cyclic tissue breakdown and regeneration. Biochim Biophys Acta 1824; 1: 146-156.
45. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174.
46. Noda M, Oh J, Takahashi R, Kondo S, Kitayama H, Takahashi C. RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 2003; 22: 167-175.
47. Casslen B, Gustavsson B, Angelin B, Gafvels M. Degradation of urokinase plasminogen activator (UPA) in endometrial stromal cells requires both the UPA receptor and the low-density lipoprotein receptor-related protein/alpha2- macroglobulin receptor. Mol Hum Reprod 1998; 4: 585-593.
48. Lescaille G, Menashi S, Cavelier-Balloy B, Khayati F, Quemener C, Podgorniak MP et al. EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression. BMC Cancer 2012; 12: 115.
49. Quemener C, Gabison EE, Naimi B, Lescaille G, Bougatef F, Podgorniak MP et al. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res 2007; 67: 9-15.
50. Lobato MN, Rabbitts TH. Intracellular antibodies and challenges facing their use as therapeutic agents. Trends Mol Med 2003; 9: 390-396.
51. Jana S, Chakraborty C, Nandi S, Deb JK. RNA interference: potential therapeutic targets. Appl Microbiol Biotechnol 2004; 65: 649-657.
52. Gotoh A, Nagaya H, Kanno T, Tagawa M, Nishizaki T. Fiber-substituted conditionally replicating adenovirus Ad5F35 induces oncolysis of human bladder cancer cells in in vitro analysis. Urology 2013; 81: 920.e7-11.
53. Yu D, Jin C, Ramachandran M, Xu J, Nilsson B, Korsgren O et al. Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures. PLoS One 2013; 8: e54952.
54. Ni S, Bernt K, Gaggar A, Li ZY, Kiem HP, Lieber A. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. Hum Gene Ther 2005; 16: 664-677.
55. Schagen FH, Ossevoort M, Toes RE, Hoeben RC. Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. Crit Rev Oncol Hematol 2004; 50: 51-70.
56. Liu Y, Tuve S, Persson J, Beyer I, Yumul R, Li ZY et al. Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models. Cancer Gene Ther 2011; 18: 407-418.
57. Hsu HH, Liu CJ, Shen CY, Chen YJ, Chen LM, Kuo WH et al. p38alpha MAPK mediates 17beta-estradiol inhibition of MMP-2 and -9 expression and cell migration in human lovo colon cancer cells. J Cell Physiol 2012; 227: 3648-3660.
58. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, Sogayar MC. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009; 9: 1-11.
59. Janssens N, Janicot M, Perera T, Bakker A. Housekeeping genes as internal standards in cancer research. Mol Diagn 2004; 8: 107-113.